Home › Companies › ABOS

Acumen Pharmaceuticals

ABOS Lead: Phase 2 3 Biotech Distilled articles ↓

Neurology Protein

Most recent annual filing: 2026-01-15

Pipeline (2 active programs)

sabirnetug

ACU193

Protein Target: amyloid beta oligomers, AβOs, amyloid-beta oligomers

Alzheimer's Disease Phase 2 intravenous
Alzheimer's Disease Phase 1 subcutaneous Halozyme

Technology platforms

EBD · JCR Pharmaceuticals

Enhanced Brain Delivery — blood-brain barrier-penetrating, amyloid-beta oligomer-targeted antibody delivery platform (J-Brain Cargo technology from JCR Pharmaceuticals); focus area: Alzheimer's disease. Preclinical candidates demonstrated 14-40x higher brain levels in non-human primates vs native antibodies. IND filing targeted mid-2027.

Targets: amyloid beta oligomers, AβOs, transferrin receptor, TfR

ENHANZE · Halozyme

Halozyme's proprietary drug delivery technology used for subcutaneous formulation of sabirnetug; focus area: Alzheimer's disease.

Biotech Distilled coverage (3)

2026-03-28 UPDATE: Acumen Pharmaceuticals (ABOS) - 10-K Drop: The Dilution Gap is Officially Closed 🔒 Paid
2026-03-21 UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Closes, Smart Money Enters, and the Science Delivers 🔒 Paid
2026-02-18 Acumen Pharmaceuticals (ABOS): Scientific Deep Dive for Sabirnetug 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.